44.211.239.1
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Retina

Risk of general IOI higher after brolucizumab injection compared to aflibercept in nAMD

Posted on

Although there was no difference between brolucizumab injection and aflibercept injection in the incidence of severe sight-threatening intraocular inflammation (IOI) in patients with neovascular age-related macular degeneration (nAMD), a significantly higher risk of generalized IOI after brolucizumab relative to aflibercept was demonstrated in a new meta-analysis.

A systematic search identified 14 randomized controlled trials including 6759 eyes at baseline comparing IOI after intravitreal anti-vascular endothelial growth factor injections in nAMD.

The risk of endophthalmitis and retinal vascular occlusion was similar amongst agents.

Brolucizumab had a higher incidence of generalized IOI (risk ratio = 6.24, 95% confidence interval = [1.40-27.90]) and vitreous haze/floaters (risk ratio = 1.64, 95% confidence interval = [1.00-2.67]) when compared with aflibercept.

Reference
Patil NS, Dhoot AS, Popovic MM, et al. Risk of intraocular inflammation after injection of antivascular endothelial growth factor agents: A meta-analysis. Retina. 2022;42(11):2134-2142. doi: 10.1097/IAE.0000000000003582. PMID: 36269802.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-